08:00 , Nov 9, 2015 |  BC Week In Review  |  Company News

Alteogen, 3SBio deal

Alteogen granted 3SBio exclusive rights to develop and commercialize ALT-P7 in China, including Hong Kong and Macau. The preclinical antibody-drug conjugate inhibitor of EGFR2 ( HER2 ; ErbB2 ; neu) is based on Alteogen’s NexMab...